BCL3 and colorectal carcinoma: Epidemiological studies suggest that the aminosalicylate 5-ASA (Mesalazine) may reduce the risk of colorectal cancer in patients with UC.48, 49 It was therefore interesting to note that treatment with 5-ASA suppresses BCL-3 expression in a number of colorectal carcinoma cell lines (figure 8).